Orient Pharma’s long-acting schizophrenia injection completes dosing of first participant worldwide in Phase I trial - Global Bio & Tech Monthly
Summary not yet available
Facts
- 瑩碩生技 (6677)
Companies mentioned:瑩碩生技、FDA
302 received, 302 listed, 6 sources ・ Page 4 of 4
One place for news and notices from 2 countries/regions: Taiwan, 152 items from 5 sources; Japan, 150 items from 1 source.
One edition every 180 minutes: every item from every source received in the period, with the original link.
Summary not yet available
Facts
Companies mentioned:瑩碩生技、FDA
Summary not yet available
Facts
Companies mentioned:Heho健康